This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Immunomedics Announces IMMU-132 Is Active In Patients Refractory To Irinotecan

NEW YORK, Nov. 8, 2013 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that some patients who had failed prior therapy with irinotecan or camptosar, both topoisomerase-1 inhibitors, responded to IMMU-132, the Company's lead antibody-drug conjugate (ADC) in clinical development for the treatment of patients with solid cancers.

Dr. Allyson Ocean of Weill-Cornell Medical College, New York, NY, was invited by the Program Chairs to present the updated results at the Symposium, which is jointly organized by the Mount Sinai School of Medicine and the Chemotherapy Foundation, a non-profit organization supporting cancer research, in collaboration with The Tisch Cancer Institute.

An overall disease control rate of 82% in 22 computed tomography-assessable patients were reported. These include 15 patients with stable disease as their best response and 3 patients, one in each of triple-negative breast, colorectal and small-cell lung cancers, with a partial response.

For the 18 patients who responded to IMMU-132, 8 had failed prior therapies with irinotecan or camptosar. Because irinotecan is the parent of SN-38, the Company's drug of choice in IMMU-132, we postulate that the increased amount of SN-38 delivered to the tumors by IMMU-132 overcomes the tumor's resistance to this class of drugs.

"We are enthused that IMMU-132 has shown activity in a patient population with advanced, difficult-to-treat solid cancers that are refractory to multiple prior therapies including irinotecan," commented Cynthia L. Sullivan, President and Chief Executive Officer of Immunomedics. "The trial has been expanded to a Phase II and is enrolling patients rapidly. We look forward to reporting results from this proof-of-concept trial," Ms. Sullivan added.

In addition to the 25 patients enrolled into the Phase I, dose-escalation part of the study, 18 patients have now been enrolled into the expanded Phase II trial. These Phase II patients include 8 with pancreatic cancer, 7 with colorectal cancer, and one patient each with ovarian, triple-negative breast, and gastric cancers.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs